Iodixanol. A review of its pharmacodynamic and pharmacokinetic properties and diagnostic use as an x-ray contrast medium.

Abstract:

:Iodixanol is an iso-osmolal nonionic dimeric hydrophilic contrast agent. It has similar diagnostic efficacy to that of other iodinated contrast media. Because of its physical properties, iodixanol would be expected to produce a lower incidence of adverse events than other nondimeric contrast media. Indeed, pharmacodynamic studies indicate that iodixanol has fewer cardiovascular effects, causes less renal damage and is associated with similar or smaller changes to the blood-brain barrier and neurological function when compared with nondimeric nonionic contrast media. In clinical trials, iodixanol had a similar tolerability profile to other nonionic contrast media but induced fewer adverse events than ioxaglate. Iodixanol appears to have an advantage over other contrast media in that it generally causes less frequent and less intense discomfort on injection. However, in common with other newer, and usually nonionic, contrast media, iodixanol is expensive. Studies investigating other nonionic contrast media (but not iodixanol) have shown that it is not cost-effective in all patients to replace older, usually ionic, contrast media with the more costly newer alternatives. Nonetheless, in selected patients who are considered at increased risk of contrast medium-associated adverse events, nonionic agents should be used. Iodixanol, with its lower intensity (and possibly frequency) of discomfort, may be a preferred option in these patients.

journal_name

Drugs

journal_title

Drugs

authors

Spencer CM,Goa KL

doi

10.2165/00003495-199652060-00013

subject

Has Abstract

pub_date

1996-12-01 00:00:00

pages

899-927

issue

6

eissn

0012-6667

issn

1179-1950

journal_volume

52

pub_type

杂志文章,评审

相关文献

DRUGS文献大全
  • Etanercept: a review of its use in autoimmune inflammatory diseases.

    abstract::With its approval more than 15 years ago, subcutaneous etanercept (Enbrel(®)) was the first biological disease-modifying antirheumatic drug (bDMARD) and the first tumour necrosis factor inhibitor to be approved for use in rheumatic diseases. Etanercept remains an important cost-effective treatment option in adult pati...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-014-0258-9

    authors: Scott LJ

    更新日期:2014-08-01 00:00:00

  • Quinolone activity against anaerobes: microbiological aspects.

    abstract::Currently available quinolones are either inactive or marginally active against anaerobic bacteria. This review summarises the in vitro activity of currently available as well as experimental quinolones against clinically significant anaerobic bacteria. Quinolones with low activity against anaerobes include ciprofloxa...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199500492-00012

    authors: Appelbaum PC

    更新日期:1995-01-01 00:00:00

  • Sickle cell disease in children.

    abstract::Early identification of infants with sickle cell disease (SCD) by newborn screening, now universal in all 50 states in the US, has improved survival, mainly by preventing overwhelming sepsis with the early use of prophylactic penicillin. Routine transcranial Doppler screening with the institution of chronic transfusio...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11632890-000000000-00000

    authors: Meier ER,Miller JL

    更新日期:2012-05-07 00:00:00

  • The relevance of serotonin antagonism in the treatment of hypertension.

    abstract::The role of serotonin in the pathogenesis of hypertension is not clear. Serotonin is produced by the enterochromaffin cells of the gut; the greater part of this is metabolised in the liver and lungs and nearly all of the remainder is taken up by the platelets. Consequently, circulating levels of serotonin are extremel...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198800361-00011

    authors: Doyle AE

    更新日期:1988-01-01 00:00:00

  • Insulin degludec and insulin degludec/insulin aspart: a review of their use in the management of diabetes mellitus.

    abstract::Insulin degludec (Tresiba(®)) is an ultra-long-acting insulin analogue that is also available as a coformulation with rapid-acting insulin aspart (insulin degludec/insulin aspart) [Ryzodeg(®)]. Insulin degludec has a flat, stable glucose-lowering profile with a duration of action of >42 h, and less within-patient day-...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-013-0051-1

    authors: Keating GM

    更新日期:2013-05-01 00:00:00

  • Gemfibrozil. A reappraisal of its pharmacological properties and place in the management of dyslipidaemia.

    abstract::Gemfibrozil improves lipid and apolipoprotein profiles, particularly very low density lipoprotein (VLDL) triglyceride and high density lipoprotein (HDL) cholesterol levels, in patients with dyslipidaemia when administered at a total daily dose of 900 or 1200 mg. As demonstrated by the Helsinki Heart Study, these effec...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199651060-00009

    authors: Spencer CM,Barradell LB

    更新日期:1996-06-01 00:00:00

  • Safety and tolerance data from the Belgian multicentre study of anisoylated plasminogen streptokinase activator complex versus heparin in acute myocardial infarction.

    abstract::In the European Multicentre Study (EMS), the safety and efficacy of a single 30U intravenous injection of anisoylated plasminogen streptokinase activator complex (APSAC) was studied in patients with acute myocardial infarction. The present study discusses the Belgian data on safety and tolerance from the EMS study. 87...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-198700333-00055

    authors: Bossaert LL

    更新日期:1987-01-01 00:00:00

  • Invasive oesophageal candidiasis: current and developing treatment options.

    abstract::Oesophageal candidiasis is frequently one of the first signs of HIV infection, and a marker of HIV disease. Approximately 10% of patients with AIDS or other immunodeficiency, whether due to an underlying disease, chemotherapy or radiation therapy, will experience oesophageal candidiasis during their lifetime. In addit...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200363100-00004

    authors: Vazquez JA

    更新日期:2003-01-01 00:00:00

  • Trifluridine: a review of its antiviral activity and therapeutic use in the topical treatment of viral eye infections.

    abstract::Trifluridine (trifluorothymidine) is an antiviral agent for topical use in the eye, and is structurally related to idoxuridine. In vitro studies have shown that it effectively inhibits the replication of herpes simplex virus type 1, which causes primary keratoconjunctivitis and recurrent epithelial keratitis in man. I...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198223050-00001

    authors: Carmine AA,Brogden RN,Heel RC,Speight TM,Avery GS

    更新日期:1982-05-01 00:00:00

  • The use of quinolones in developing countries.

    abstract::The size of the antibiotic market in developing countries is double that seen in developed countries. There are some valid reasons for this difference, one of which is the higher frequency of diverse infections in the developing world. However, other factors are involved: for example, antibiotics are available without...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199300453-00009

    authors: Rodríguez-Noriega E,Morfin-Otero R,Esparza-Ahumada S

    更新日期:1993-01-01 00:00:00

  • Insulin glargine: an updated review of its use in the management of diabetes mellitus.

    abstract::Insulin glargine is a human insulin analogue prepared by recombinant DNA technology. Modification of the human insulin molecule at position A21 and at the C-terminus of the B-chain results in the formation of a stable compound that is soluble at pH 4.0, but forms amorphous microprecipitates in subcutaneous tissue from...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验,评审

    doi:10.2165/00003495-200363160-00007

    authors: Dunn CJ,Plosker GL,Keating GM,McKeage K,Scott LJ

    更新日期:2003-01-01 00:00:00

  • Haematological effects of anisoylated plasminogen streptokinase activator complex and streptokinase in patients with acute myocardial infarction. Interim report of the IRS II Study.

    abstract::86 patients with a first myocardial infarction presenting within 6 hours of the onset of symptoms were randomly allocated to treatment with intravenous streptokinase or anisoylated plasminogen streptokinase activator complex (APSAC). Plasma concentrations of fibrinogen, plasminogen, alpha 2-antiplasmin and fibrinogen ...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-198700333-00046

    authors: Monassier JP,Hanssen M

    更新日期:1987-01-01 00:00:00

  • Pharmacotherapy for obesity.

    abstract::Pharmacotherapy for the management of obesity is primarily aimed at weight loss, weight loss maintenance and risk reduction, and has included thyroid hormone, amphetamines, phentermine, amfepramone (diethylpropion), phenylpropanolamine, mazindol, fenfluramines and, more recently, sibutramine and orlistat. These agents...

    journal_title:Drugs

    pub_type: 杂志文章,meta分析,评审

    doi:10.2165/00003495-200565100-00006

    authors: Ioannides-Demos LL,Proietto J,McNeil JJ

    更新日期:2005-01-01 00:00:00

  • Optimal pharmacological therapy for community-acquired pneumonia: the role of dual antibacterial therapy.

    abstract::The optimal pharmacological therapy of community-acquired pneumonia (CAP) is one of the most ardently debated issues in medicine. Presently, most guidelines recommend either a fluoroquinolone alone or dual therapy with a third-generation cephalosporin plus a macrolide in patients hospitalised with CAP, but few provide...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200565140-00004

    authors: Epstein BJ,Gums JG

    更新日期:2005-01-01 00:00:00

  • Entecavir: a review of its use in chronic hepatitis B.

    abstract::Entecavir (Baraclude) is a novel nucleoside analogue of 2'-deoxyguanosine whose intracellular triphosphate form inhibits replication of the hepatitis B virus (HBV). In large, randomised, double-blind, phase III clinical trials in patients with chronic HBV infection, oral entecavir 0.5 or 1.0mg once daily for up to 96 ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200666120-00009

    authors: Robinson DM,Scott LJ,Plosker GL

    更新日期:2006-01-01 00:00:00

  • Effect of felodipine and metoprolol on muscle and skin arteries in hypertensive patients.

    abstract::The antihypertensive and vasodilator effects of felodipine, a new calcium antagonist of the dihydropyridine group, were examined in 15 patients with moderate to severe hypertension. Flow was measured simultaneously at the calf and finger using a venous occlusion ECG-triggered plethysmograph. Measurements were made at ...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198500292-00024

    authors: Clement DL,De Pue NY

    更新日期:1985-01-01 00:00:00

  • Second-generation antihistamines: a comparative review.

    abstract::Second-generation histamine H1 receptor antagonists (antihistamines) have been developed to reduce or eliminate the sedation and anticholinergic adverse effects that occur with older H1 receptor antagonists. This article evaluates second-generation antihistamines, including acrivastine, astemizole, azelastine, cetiriz...

    journal_title:Drugs

    pub_type: 杂志文章,meta分析

    doi:10.2165/00003495-199957010-00004

    authors: Slater JW,Zechnich AD,Haxby DG

    更新日期:1999-01-01 00:00:00

  • Lemborexant: First Approval.

    abstract::Lemborexant (DAYVIGO™) is an orally administered, dual orexin receptor (OXR) antagonist that exhibits reversible competitive antagonism at OXR1 and OXR2 (> affinity at OXR2) that was discovered and developed by Eisai Inc. for the treatment of adult patients with insomnia. In December 2019, lemborexant received its fir...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01276-1

    authors: Scott LJ

    更新日期:2020-03-01 00:00:00

  • Teicoplanin. A reappraisal of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy.

    abstract::Since an earlier review in the Journal substantial additional data have accumulated, further clarifying the in vitro activity, pharmacokinetic profile, clinical efficacy and tolerability of teicoplanin. Recent therapeutic trials confirm the efficacy of teicoplanin in the treatment of microbiologically confirmed Gram-p...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199447050-00008

    authors: Brogden RN,Peters DH

    更新日期:1994-05-01 00:00:00

  • Renal protection in hypertensive patients: selection of antihypertensive therapy.

    abstract::Hypertension is common in chronic renal disease and is a risk factor for the faster progression of renal damage, and reduction of blood pressure (BP) is an efficient way of preventing or slowing the progression of this damage. International guidelines recommend lowering BP to 140/90 mm Hg or less in patients with unco...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200565002-00005

    authors: Wenzel RR

    更新日期:2005-01-01 00:00:00

  • Clinical pharmacology and modification of autoimmunity and inflammation in rheumatoid disease.

    abstract::The increased understanding of the mechanisms which underlie rheumatoid disease has been accompanied by a more appropriate use of the limited repertoire of therapeutic agents. Conventional second-line drugs still have a role in everyday practice. The efficacy of these agents in reducing the severity of clinical signs ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199447020-00003

    authors: Luqmani R,Gordon C,Bacon P

    更新日期:1994-02-01 00:00:00

  • Clinical Implications of P-Glycoprotein Modulation in Drug-Drug Interactions.

    abstract::Drug-drug interactions (DDIs) occur commonly and may lead to severe adverse drug reactions if not handled appropriately. Considerable information to support clinical decision making regarding potential DDIs is available in the literature and through various systems providing electronic decision support for healthcare ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-017-0729-x

    authors: Lund M,Petersen TS,Dalhoff KP

    更新日期:2017-05-01 00:00:00

  • Drug stimulated biotransformation of hormonal steroid contraceptives: clinical implications.

    abstract::On the basis of well documented biochemical and pharmacological data about the influence of drug mediated enzyme induction on the biotransformation of natural and synthetic sex steroids, practical consequences for hormonal steroid contraception are described and discussed. Clinical reports dealing with this problem ar...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-197612060-00003

    authors: Hempel E,Klinger W

    更新日期:1976-12-01 00:00:00

  • Drug-induced hypertension: pathogenesis and management.

    abstract::Estrogenic compounds are the most important group of drugs that can induce hypertension. Studies have shown an incidence of significant hypertension amounting to less than 1% after 1 year of taking oral contraceptives and about 2% after 5 years. The ratio of the incidence of hypertension among ''takers'' to that of ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-197612030-00005

    authors: Stokes GS

    更新日期:1976-01-01 00:00:00

  • Ciclesonide nasal spray: in allergic rhinitis.

    abstract::Ciclesonide nasal spray delivers the corticosteroid ciclesonide as a hypotonic spray via a metered-dose manual pump. Systemic exposure to ciclesonide and its active metabolite desisobutyryl-ciclesonide is low after intranasal administration. High protein binding (approximately 99%) and rapid first-pass clearance furth...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200868060-00009

    authors: Dhillon S,Wagstaff AJ

    更新日期:2008-01-01 00:00:00

  • NSAIDs and gastrointestinal cancer prevention.

    abstract::Numerous studies report the relationship between aspirin and other nonsteroidal anti-inflammatories (NSAIDs) and cancer incidence, in particular for colorectal cancer. This paper systematically reviews the evidence of the effect of aspirin and other NSAIDs on the primary prevention of colorectal and other gastrointest...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200262060-00006

    authors: Jolly K,Cheng KK,Langman MJ

    更新日期:2002-01-01 00:00:00

  • Parenteral aminoglycoside therapy. Selection, administration and monitoring.

    abstract::Aminoglycosides are potent water-soluble antibiotics, with peak concentration-dependent bactericidal activity against many pathogenic aerobic Gram-negative bacilli and Staphylococcus aureus. For systemic therapy, they must be given parenterally (intravenously or intramuscularly). In the body they remain largely extrac...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199447060-00004

    authors: Kumana CR,Yuen KY

    更新日期:1994-06-01 00:00:00

  • Cibenzoline. A review of its pharmacological properties and therapeutic potential in arrhythmias.

    abstract::Cibenzoline is a class I antiarrhythmic drug with limited class III and IV activity which can be administered orally or intravenously. An elimination half-life of about 8 to 12 hours permits twice daily administration, although age and renal function must be considered when determining dosage. Cibenzoline has some act...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199243050-00008

    authors: Harron DW,Brogden RN,Faulds D,Fitton A

    更新日期:1992-05-01 00:00:00

  • Gastro-oesophageal reflux disease: beyond proton pump inhibitor therapy.

    abstract::Gastro-oesophageal reflux disease (GORD or GERD) is a very common disorder, and advancement in drug development over the years has markedly improved disease management. Proton pump inhibitors (PPIs) remain the mainstay of treatment for GERD due to their profound and consistent inhibitory effect on acid secretion. Howe...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/11597300-000000000-00000

    authors: Hershcovici T,Fass R

    更新日期:2011-12-24 00:00:00

  • Temocillin concentrations in human tissues.

    abstract::67 samples of 15 different tissues were obtained from 26 patients who were given an intravenous bolus dose of temocillin approximately 3 to 4 hours prior to surgery. 50 tissue samples were obtained from 19 patients who received 1g temocillin and 17 tissue samples were obtained from 7 patients who received 2g temocilli...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-198500295-00034

    authors: Gould JG,Meikle G,Cooper DL,Horton R

    更新日期:1985-01-01 00:00:00